AstraZeneca, Rivals Take Aim at Lung Cancer Combo Therapies

Updated on
  • Astra aims to be first to market with first-line combination
  • Bristol-Myers Opdivo failure emboldens immune oncology rivals

For AstraZeneca Plc, when it comes to beating cancer there’s strength in numbers.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.